Catalyst Pharmaceuticals (CPRX) 11 May 232023 Q1 Earnings call transcript

Greetings and welcome to the Catalyst Pharmaceuticals first quarter 2023 financial results conference call.

At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require Operator assistance during the conference, please press star, zero on your telephone keypad.

As a reminder, this conference is being recorded.

pleasure your my Chief Ali now Officer. Financial is to host, introduce Grande, It you may Ali, you Thank begin.

financial highlights. everyone. our Patrick discuss XXXX conference morning McEnany, call and Good Thank Executive to Catalyst’s you Chairman and first Officer. today the call Leading for Chief joining results is corporate quarter

Gary Further, Steven will We and our Carmen, Jeffrey Dr. Chief our for Q&A Officer we Miller, Ingenito, Officer. session, the are Dr. and also joined and Medical Operating have Del Chief our by Regulatory Chief Officer, Chief Commercial Scientific Officer.

and securities like Before not estimates difficult I Actual that Q&A be to assumptions are remind begin, guarantees expectations, uncertainties statements involve our statements. purposes which prove of are results we They in laws. vary current the in will forward-looking federal and remarks we morning may would future about These to risks, the to and in not statements expectations be performance. you results our future for contained from may our and and forward-looking relate may that expected accurate. make this statements to predict session, of projections

the our contained XX-K. should The the factors information in filings, considered in XXXX in risk including our conjunction be detailed described annual report SEC Form with only forward-looking statements on

this I’ll call turn over the to At time, Pat.

Thanks Ali, and welcome everyone quarter XXXX to conference call. our results first

made across in on key our and all shared we progress will release, functional very meaningful performance as first record-breaking highlight our report I strong quarter pleased press several I’m XXXX to started XXXX points. We yesterday’s now as areas. financial

first net Total owned XXXX that year-over-year. the product were net XX% net reflects two U.S. approximately growth $XX.X bolstered million, million million of performance the of revenues months for year-over-year. product revenue XX% during increase the of rights exceptional we The a the $XX.X Fycompa total representing quarter, quarter. achieving Firdapse achieved the product revenues to $XX.X by revenues of We during revenues

expenses net stock-based quarter basic net period, related of $X.XX assets, first the per in and amortization per cash Fycompa depreciation, This intangible Fycompa non-cash million. approximately non-cash income $X.XX basic million was ended income $X.XX $X.XX was share million the $XX.X reflects million GAAP Ruzurgi, GAAP $X.X agreement the among quarter million of and stock-based for share Eisai per and about tax the with $X other to the expenses million, services which income and were the related first of $X.X or expenses diluted quarter for and amortization share. associated compensation, provision. diluted from position assets $XXX were of per the the Non-GAAP approximately for the compensation. share, two-month $XX.X acquisition income which or We transition with our for a to with intangible excludes the

performance quarter increase in XXXX. between first $XXX and revenue belief to XX% total total to outstanding reinforces to the million, guidance of our $XXX a XX% The strategy representing compared XXXX we revenue in reaffirm million

expenses of the We also $XXX still million for directly $XX which full This which Fycompa acquisition. million per the mind for Fycompa, pro $XX million year. time account be fine-tuning we to Keep we $XX to expenses this to that at in forma are estimate our amortization related about the XXXX, to operating for expect includes year $XXX includes million expenses of to year. this million expenses operating

also be between million. are non-GAAP $XXX million XXXX for to net will income that $XXX We forecasting

receptor with marks only growth XX, the XXXX. the completed epilepsy, During Fycompa revenue AMPA This first strong by non-competitive that the product first an rights antagonist successfully we for of already of quarter, purchase our further we Catalyst and as January commercial have milestone important U.S. the we Firdapse. announced for augmenting broadened to the portfolio

brand, as including Fycompa engaged of and part actively commercial is Fycompa the on-boarded the this and we am medical to for that activities. completed I support full integration commercial marketing, newly X, are for affairs pleased week. our the field teams May promotion Effective medical franchise U.S. most the report team established

welcome a and term wealth to targeted from bring family. income that to new exceptional position diversified We opportunity. Building benefit synergies to passion, rate Fycompa benefit are the we to revenue team Catalyst are in and achieve field members our Catalyst from expertise upon the this capabilities, long run excited commercial who experience fully to our our epilepsy of portfolio poised

agency clinical Moving on progressing by South Japanese of and LEMS of in study, focused regulatory anticipate partner, in expanding is market onto countries assuming anticipate DyDo plan America. registrational Japan, The we on completion success quarter in new our in an III NDA acceptance NDA in of Japan Pharma plan. are expansion the We other end we by submission upon Firdapse progress Based an our strategy and business, and, meaningful global our of study the the for study growth that Phase Asia accelerate in to also XXXX. XXXX second making to Central product use to we Firdapse. the the

number partnership to already milligrams these benefit milligrams we global the quite from XXX are there per milligrams the term day, plans, also per day are with with of dose patients opportunities an longer being Firdapse know Along Firdapse per from Initiatives we in growth strategic as underway as XX day. seek of expansion to that part treated maximum daily our our FDA of planning a to in territories plans. identify are from XXX potential increase could

the daily FDA change application meeting filing third the to Just regarding XX we received from the Based year. for expand we the the from seeking SNDA last the approval the dosage the XXX this positive NDA week, supplemental our to Firdapse C seeking of of for quarter meeting, maximum in anticipate the the from response minutes on Type requirements submission milligrams. early with

disease portfolio. a rare we During this diversified acquisition ground towards identifying significant opportunities gained quarter, in building

to acquisition of and/or remains partnerships, global assets, through on stage own those of priority product that assets. companies strategy commercial the of broaden continue portfolio key diversify acquisitions Our collaborative to type our smartly front and

perspectives from add or rare preference stage and multiple company programs is Our late commercial tuck-in is a to resourced neurology assets. with towards fully capacity in there disease

Our our improve who and our is since and initiatives the that forward strategy from of as people effective This we affordability earlier are and to in to With commitment continue safe to we medicine that journey communities. rare and inception, has we those diseases. ESG providing treat core patients benefit our ESG highlighting to inaugural on governance difficult mission, suffer foundation. advancing our share and our our values. while and mind, driven lives progress enabling building with sustainable month, which released accessibility remains our and to report this environmental, that patients, social look to strong We commitment proud these

Without expectations. meaningful performance achieved financial we that exceptional question, results successfully as executed we an exceeded multiple delivering across while initiatives

growth our our we for our value will achievements. sustained various prudent our products a drive ahead, to capabilities expanding positioned approach are branded well and sustainable by Looking and our vision to for Coupled future stakeholders. strategy recent with deliver long executing all continue growth sound capital two we for and term with company’s supported our allocation,

an on Jeff Del I’ll provide call Carmen, activities. will commercial our Officer, our over the to now update Chief who Commercial turn

good morning Pat, Thanks and everyone.

total of revenues the Pat of combination million an revenues from guidance revenues combined driven Catalyst record $XXX start XXXX positions compelling QX The strong had As and to Firdapse well Fycompa. million $XXX net Catalyst mentioned, excellent XXXX to by achieve $XX.X net revenue our to of million.

all a XX% represents me QX year, sales consistent compliance, a or are $X with increase commercial order cadence enrolled Prescription million covered co-pay in sustained less patient Catalyst Patients including of $XX.X rates those and average accessing net Firdapse assistance, insurers. result approval by new had payors, greater rates. pathways, First, same XX% of were of than than quarter who starts, low and last per direct discontinuation of Medicare performance. month. an private start over the let high foundation government a across

drive channel targeting resulted which for antibody the have initiatives forward. increase Firdapse. programs more for moving healthcare journey patients to shorten tests, significant lead in education treatment a being strategic with will voltage patients organic LEMS Our continue growth and to calcium gated LEMS providers growth already in diagnostic will eligible

thought cancer LEMS patients cancer on thoracic of accelerate top hired diagnosis cell the oncology to small XX the undiagnosed. LEMs leader focus patients. lung Currently oncology lung liaison of will Additionally, are greater small centers recently XX% than

continue approximately new maintain pipeline to XXX on are XX% each We around yet not quarter. of a diagnosed contributes patients Firdapse patient enrollments that LEMS of which

on Fycompa. update provide let Now me an

experienced business team a established gone and to a our personnel has Fycompa Firdapse organization execute living and new synergistic entire Fycompa our the The of sales without with credit exceptionally staffed interruption to understanding with the with patients have highly well, franchise commercial flawlessly force that are a marketing is a to fully to business. commercial capability Firdapse XX integration The deep Fycompa We and help passion epilepsy. business. with highly

During the commercial into were growth business Fycompa and were opportunities. franchise X. Fycompa XX week three regional meeting meeting, our and entire effective held the managers was corporate our team Fycompa May, first Fycompa successfully area account Fycompa energized launch of deployed The all of team and our we leadership On about which directors sales of future in team launch field May certified. conclusion our trained the

towards two million. physician an for months will to our the $XX.X franchises which XX% overlap the benefit Firdapse the and infrastructure our increased $XXX of owned QX voice Fycompa with further growth. Fycompa [indiscernible] in approximately in confidence full of forecast driving for product, strategic that ideal rights net is XXXX portfolio achieving our share Fycompa year Fycompa and an Adding product a fit net were adds commercial to existing both revenues million for that U.S. we revenue

on of progress as successful summary, we Fycompa sustained making the execution our for are growth well of the launch In as organic commercial meaningful Firdapse business.

and our total focused $XXX $XXX in million. highly of excellence million remain execution continued and are guidance confident revenue to on We commercial XXXX

unwavering I at to to commitment want a thank and entire the team XXXX. forward Catalyst look patients their successful for to

to update turn Officer Operating and now Chief I Officer Scientific on activities. R&D an will over Miller, Dr. our Steven Chief call the for

Thanks Jeff.

for development strategy Fycompa focus organization. patients, newly access to integrating Firdapse continues state Firdapse commercial regulatory potential and LEMs the into Catalyst’s expanding patented acquired to the product and maximize Our to all enhancing on clinical its

day dose XX would to per efforts our First, to Firdapse increase of XXX maximum I from milligrams milligrams. to the discuss like indicated development

XX agency at Currently, are Firdapse milligram insurance this expect be As treated the in of increase of dose justify patients per this who the that filing those are their daily dosage there to higher maximum a providers already pharmacy being milligrams XXX the has therapy, the approach supplemental a planned approved, daily will milligrams maximum the constitutes Other believe current their patients submitted dosage for need of of on and quarter year. LEMS basis that the NDA that physician indicate Firdapse. to this SNDA accept expressed acceptable they help patients. supplement, and the a set an data to our responded third have the day to worked earlier week, dose. our seeking daily with a announced dosage if optimize submission patient’s XXX after and indicated early we a physicians of XXX milligram We for number to to

to Regarding Japanese is Firdapse safety partner, in for of Phase is DyDo study phase ongoing. follow-up the completed required trial the their and our market, III our seek expansion, global clinical enrollment has sub-licensee Japan, Pharma that which in approval

Japanese South Firdapse year expands of Catalyst the filing completion for quarter markets Japan. other our agreement, that XXXX. into and is and LEMS advancing anticipate efforts a Japan the an further about expand to X,XXX of is it and estimated the our continue our in of Central the of there trial filing submission in Under license second global of to and in footprint X,XXX of NDA We to by end Asia because important It in are NDA the the territory, Firdapse milestone that patients America. in

efforts as first perampanel, Fycompa, successful receptor previously approved Jeff are of inhibitor. have reported, integration progressing is we we the Catalyst’s or and and the AMPA the As or recently completed rights to U.S. of well, which completed antagonist only commercial the teams. acquisition integration the reported, Fycompa

quarter functions We this distribute into also pharmacovigilance along by the and and fourth the organization process to well with of trade anticipate beginning dress Fycompa’s are integrating in our Catalyst Fycompa of year. manufacturing, quality

these an duration AMPA over-activation secondary and of control. effects central receptors believe seizure spreading be receptors Hyperactivation Hyperactivity AMPA the function that actually also and induced alter AMPA generation throughout nervous as and transmission fast can system. excitation. AMPA excitatory it on toxic is receptor of receptors. receptor enable epileptologists can might of improve highly reverse Fycompa seizures and Epileptologists antagonist dependent synaptic AMPA adds [indiscernible]. by believe to seizure

Fycompa without are medication XX four secondary to treat age in people with years and partial primary and seizures onset in generalized to seizures older. is of as other are seizures medications epilepsy anti-seizure generalized who older years approved tonic-clonic with an epilepsy age people of who treat with or with and

in use patient’s Oncologists strength, that practices patients. physician’s and ability to patients Firdapse have improving Moving oncology of of provide treated the onto already function, healthcare medical relationships MSLs, information patients Firdapse to education are about found patient’s testing with those their wellbeing maintained liaisons, functional Catalyst’s out our maintain perceptions their the build science the LEMS the order in reaching and actively medical expand neuromuscular importance providers to and by for ability. treat to LEMS that muscle of or

patient’s of All of critical quality the domains life. for these are

also all with extensive epilepsy mature new product any data to these and epilepsy and physicians also to and published has information will is bring the MSL treat information Fycompa. MSL Fycompa. on-boarded may Fycompa experience available. this using Fycompa director, to have address new The about to that their questions providers team for healthcare real-world prior support Catalyst team a which is

recent publication reported, previously to respond to a treatment. rare As that epilepsies shown of a identified Fycompa number were

Catalyst management taken community, service programs part three education to past CME healthcare to maintenance continuing the Catalyst this LEMS ongoing support this the the the we various oncologists medical new and physician X,XXX support over the of associated formal quarter, targeted order the years for Last over that CME that have have period cell test CME LEMS. about lung programs to development of three a X,XXX small their that healthcare time, a and in of for treatment the aspects providers diagnosis, provided correlation of the medical CME of utilized toward learning between for As or CME education, and provides of due program’s are granted LEMS. CME the be Over modules, treat sponsored licenses. program has providers. credit of cancer cancer

takers. Catalyst we few just are test already success may reached and these XXX factors future. contributing treatment this X,XXX CME new the one months, of of recent overall support programs In has learners of both be healthcare programs’ programs will the than the Fycompa for through to now now continue commercial Firdapse there LEMS had In far many a have for CME creation short, and success providers the to Firdapse for of LEMS. program and more these the patients, in

Moving onto to Fycompa acquisition. business potential acquisition are important Fycompa strategy. the the described first we expansion additional to out and acquisition point of with fits Pat identify continuing the is portfolio our business quarter, for assets It broader significant our how also development, into in development

with are each. epilepsy origins medicine identified field for into approach epilepsies and the numbers targeted developed evolving increasing increasing the is biochemical precision being treatment a specific rare epilepsy being being therapies of of As elucidated, of

Fycompa are rare of Catalyst’s this pursuing that development, Catalyst and expanding a rare into stage company, disease stage extend late disease. neuromuscular epilepsy or our additional is As commercial area. including beyond in very therapies products entrée actively is therapeutic those that acquisition

our time, to like call I this over turn to Grande, would Ali CFO. At the

Thanks Steve.

of year and exceptional have execution. from for set strong pace financial Results on XXXX another first quarter us Catalyst’s performance

January. of busy the two we only operations, in include Fycompa efforts of of for underway. for the the rights months the cash, quarter On development I we remind and product front, activity in since you little million very a late acquired previously first are Fycompa we that including over announced as business results were U.S. XXXX, to the acquisition $XXX the closed integration

for million. first year-over-year XXXX. compared the the January of product, quarter revenues when XXXX. total our Product for net late of Fycompa the quarter of revenue XXXX revenues increase to million, the in $XX.X quarter first were quarter for million lead Our a of $XX net of was total for compared $XX.X the to of $XX.X the XXXX a Firdapse, million, XX% was for first first first for for XXXX million XXXX acquired product increase quarter $XX.X revenue XX% Product

first of $XX.X per for share. million, income of $X.XX Net basic diluted per first of the $X.XX quarter diluted million, income million for income to million, to $XX.X XXXX $XX.X GAAP was compared quarter year-over-year XXX% for of the reported quarter $X.XX before a income net $X.XX compared or of of share, year-over-year taxes XXX% XXXX. basic per net for and per XXXX an or GAAP first quarter of increase the increase first We XXXX $XX.X the and

in of related foundation many industry, make like [indiscernible] of year, companies LEMS impacted donations are expenses in calendar commitment year. reminder, we first that the programs Further, a deductibles. patient annual quarter patient in support reported the to reset quarter to our As we to throughout the the the first our fund by charitable our

per and Non-GAAP also stock-based of for per from GAAP $XX.X non-GAAP Ruzurgi of of income of of million, $X.XX to quarter the XXX% million diluted $X.X provision was net Fycompa non-GAAP basic XXXX expense depreciation to per $X.X $X.X $XX.X It million. compensation or and of in and quarter excludes intangible related first basic stock-based represents income compares which tax of This or net an share, $XX,XXX, depreciation net million, million. of $X.X income XXXX per $X.XX compensation increase year-over-year. million million, $X.XX approximately income acquisitions excludes of our $X.XX which and provision first income an net income assets GAAP share, $X.X amortization diluted income $XX,XXX, tax from and of of the of net of

approximately the five late XXXX not quarter next We acquired January to years. amortize expect in acquired had intangibles XXXX intangibles In on we acquired we have approximately connection Fycompa connection the acquired both the basis Amortization either did during over for a million as comparable product $XXX and of any license recorded approximately first product straight-line for during July and the was in million the in product quarter XXXX. that with with not XXXX. the Ruzurgi Fycompa the in of acquired $X.X first quarter amortization we acquisition,

to our the $X.X quarter related XXXX. million of intangible rest for be products expect acquired for per amortization We approximately

quarter an the effective quarter of XXXX to on XX.X% Our XXXX. of rate tax the was first XX.X% basis for compared first annualized for

to the XX% the any For permanent credit difference is stock given future The anticipated offset state drug rate fluctuate many XXXX, is federal by options in periods. tax taxes likely the exercised claim. and annual income differences to primarily affected of driven factors, tax was statutory rate income effective and by number by including period, of the tax in orphan

were sales of compared the of approximately royalties. quarter of XXXX expenses $X.X of to principally in first first in quarter and Cost the $X.X consisted XXXX million million

X% million expect by net is exceed the higher we As reminder, Fycompa intangible product sales assets. of sales in so sales of cost when Cost exclusive were of increase year, for any in royalties progresses. as a of amortization calendar Firdapse trend XXXX $XXX year to

quarter $X.X XXXX first XXXX to $XX.X noted. where quarter be $XX.X XXXX. expenses of used of $X.X compared for XXXX in XXXX. due the commercial services the to over XXXX, principally XX% of Research organizations, The related SG&A and January and total quarter XXX(c)(X) a expenses up QX first would XXXX. for the the were contributions totaled to million the quarter our in the compared QX QX the million full of in the was transition during XXXX expenses difference in as XXXX to development previously to XXXX expenses from first first under expenses for year the decreased operating as overall first of to slightly during quarter agreement expenses slightly million percentage in contributions SG&A million of XX% Fycompa SG&A

of reported, ended $XXX As the and equivalents quarter we with cash cash million.

strategic funds cash during leading our for as and programs rights the financial As flexibility the reminder, initiatives we well remaining us U.S. available approximately million support our allow creation. continue R&D of $XXX for the acquisition of as used acquiring existing believe opportunities to XXXX of to Fycompa. fund growth January a our We future value to our

Commission Investor our detailed XX-Q our can of page More Relations report may and on performance and which website the analysis be found be quarter at found information first in financial on Exchange Securities was and yesterday, May with Form our filed www.catalystpharma.com. quarterly XX, in our XXXX

With the I’ll over turn call Pat. to that,

Ali. Thanks

prepared our position remarks, we within our closing leader very In we as space. path our forward continue a as the neuroscience about are strengthen optimistic to

are with to expansion deliver sustainable positioned healthcare core value set growth further mission and to our on We aligns with our that to well providers shareholders. patients, drive sights

employees thank I I serve. our to for of and am proud of dedication patient and ongoing communities their commitment all team’s our accomplishments the we

call this line At over to the to time, to Operator like for open I’d the the questions. turn

Thank you.

be now question session. will We a instructions] answer and [Operator conducting

Thank you.

Our from proceed first is Joon with your Please question. with Lee question Securities. Truist

Good this morning, Joon. is Thank you for Les on questions. my taking for

drove on seasonal you seen the Firdapse the in that have talk First, other Can slide about Firdapse. you I’ll sales? impacts any quarter-over-quarter and trends any start that might

slide say Firdapse in sales? you Did the

Quarter over sequentially, yes. quarter

do Jeff, Yes. want take question? that to you

QX, they reset, that the to their these Sure. shipment some in co-pays holidays, have seasonal so patients are to saw so Firdapse, typical industry but What net to forward for impacts It’s general, of as always us. for what bit, their happens pleased want January, and little factors January as--what December they just deductibles the medication well try like revenue patients of results as before that’s we in benefits drug QX. some QX. quarter, in in prescriptions a impacts very not their it’s December, ensure that get that over their do with or into such The the pull in try the to impacting we’re in

for to always manufacturing rest quarter. will first QX accrue the net throughout you in the gross the and net to rebates Medicare accrual patients that’s for into the inflated why net, you gross the Medicare year, percentage to a so of bit is growth then so see follow all Also little higher,

so part process, that in talked that about patients re-authorization don’t medication, factors first products get the mentioned, they those in that process but again like quarter. as, the happens have any most the are with their in all these for the bridge as the provide during shipments we re-authorization part the most of already well for so interruption industry we seasonal an I I that for in other January, the also have impacted

Les, be that’s especially away of for in specialty dealing one in and where patients typical only week pharmaceutical giving giving you’re Jeff typical, pretty can revenue, that’s specialty from and free which the can’t three pointed to away that to shipments, business. gave product getting with re-authorizations, that out, area away--because we bridge if will. charge as you for but delay you’re That the re-authorization, not on you’re the we anywhere distributor, waiting free a weeks, are charge - in that that’s

There I number like if are a is back will see last of skewed; exceptions, at you with of on-boarded so that’s look QX think year QX us flat. versus patients, sort typical. otherwise, but pretty was of in QX few the historically, Ruzurgi we that exceptions, you

the again, XXXX revenues well given this, I’ll Firdapse Fycompa confirm guidance strong we’ve Q. in as performance for said is it with throughout leave forecast our Firdapse, as the today, we like and for the once with call

thank wanted you for wide, if you detail. the for there to I That’s very explanation I just industry get same it’s and else, was the understand the sense impacts so or something a and helpful. if

been same the the guidance, Regarding, you that provided guidance has of shift I as on mix for lines? touched or there in you separate a quarter last still the product guess the the is

same Yes, change right there’s talked The we is about mix. now Les. time, the no in as the last proportion

okay. it, Got

rate, number? very strong Can the quarter, everyone sales imply the a do let’s upside, a around any more that that can that strong? run Fycompa we similarly run normalized we full expect is rate, reasonable months if or something quarter, Then expected, drove you normalize to what does would million be that quarters the three probably you a per on remaining we provide $XX high and than color seem If for so that street say. think

take question. as that great That’s a I’ll Jeff let well.

thing feel One What force. with you like we we’re transition quick a to allow have for Sure. going efficient any sales with doing period. integration, is more be is much our to we’re

transition personnel about perspective that for that, we of but confident XX% a the flat and our versus to we’re larger why and very hold, taking territories, allow that’s in size period field what Fycompa to take versus want previously We’re XXXX. number from used was XXXX with for

Let me like that in add to out think things so this January, and full the your for you question, Jeff of year. rebates months and extrapolate re-authorizations that, your are and Les, more those earlier can month your is product pointed I result, retail merely don’t in a a as and as affected the also of two take and

on the we’re but if would certainly provide we’ll update with XXX I think guidance, that think that be I think comfortable this for I year. a mistake, the and moment, still sitting an and that right very now changes for

that Correct, growth and Fycompa. can we are we in very demonstrate XXXX confident with

Good the luck for on progress. Guys, color. you thank the you. Thank

Thank you.

you. Thank

Catanzaro Joe from question. your with with is question Please next proceed Piper Our Sandler.

from my much so your non-tumor efforts some the with and first the is that whether LEMS on you in Maybe if new thanks of the me, of LEMs one comment oncology. cadence just can changing any questions. you’re patient taking everybody, and in way wondering split Hey quarter seeing for in tumor dynamic between enrollments and

DyDo Japan, Then if same milestones NDA a III subsequent about with wondering to then further with expansion regards related filing? sort DyDo, think should completion associated global struck Phase are collaboration there of Thanks. their to in any that way your and and of we maybe you’ve in the comments opportunities, the on with

take first question? Sure. the Jeff, want do you to

question. the here so cadence we patient enrollments QX. for that continue had thanks there strong QX enrollment Joe, far see Hi thus patient to in in we of forecasts, QX The strong in cadence a exceeded and new new

that LEMS goes, an scans, our XX% estimating code, some there LEMS those two patients mix of in get LEMS. to come in in diagnosed we we they that about mind Keep the that years Based we patients saw, over--so patients XX% with patients. we’re over new then and are next come we’re QX that factors, their so as of will the they on with as LEMS all enrollments estimate, but in be make far tumors some total about are tumor are a mix assumption, tumor have it. As ICD-XX our that enrollments are

the undisclosed with regard PMBA. transaction other serves good as regard With to global in DyDo milestone filing by Asia Joe, an to and South and on acceptance based our really model efforts, a Central territories milestones, yes, Japan and And America. for is for there Pharma

got it. Thanks for Okay, all That’s questions. my taking helpful.

Sure, Joe. thanks

you. Thank

Our Fitzgerald. Charles from proceed your Cantor Please question next with Duncan with questions. is

Hi, for Pete progress Hi Congratulations on the the for this Stavropoulos quarter. and team. on Pat Charles. is all

is you number efforts? XXX that the Firdapse, LEMS than wondering into you say of with but opportunity, give patients and First question any or treated the total can penetration what penetration what can oncology LEMS being terms suggests that diagnosed greater a are specifics there’s result outreach are there in of into as

Pete. I’ll to turn Jeff, that

a we’re we’re still about now current penetration patients that’s diagnosed and living XX% with right so are a of - it’s XX% Hey seeing is about seeing Pete. penetration. what What that LEMS,

that your with we As other about think as far far LEMS what patients, question, can the penetration? as--what we was as Pete, get tumor

asking what was the efforts I actually been Yes, has think oncology outreach you impacting--? do efforts,

lung diagnosed that are undiagnosed, benefit Okay, get excellent. We’ve help greater us is patients, patients from cancer the to be about unfortunate in they enrollments there are cell for these of hopeful is Firdapse. than patients. patients uptick of small but that to XX% so so patients of uptick into small seen the these we’re to the LEMS and LEMS up with get just new an will all-out I the get That’s treatment that what it’s can are cancer say news lung recently, cell can XX% can slight our tumor XX% our we towards. the so geared What a mix percent that or LEMS efforts

XX you of Firdapse, Okay, color can patients and in like who go any dose the proportion from milligrams? any--you would provide patients of to or XXX on to about milligrams the up the know,

will were XX higher--that LEMS or these milligrams feel also on dose, to disease, huge and a know some felt. hearing is benefit from our patients from higher. Ruzurgi patients. XX% there higher of will benefit former current patients physicians that We now LEMs these patients there a right that Yes, We patients and from patients and like be--that’s again a are progressive are of

physicians at Also, have a to you of those XX milligrams also don’t to these don’t we necessary even want that that’s that--and see having their that want are is so of do dose that’s some disease. XX dose, the some help go to to XX because benefit a max patients cap to or patients if for to XXX, dose, the allows milligrams from higher XX, patients when max that so now treat what go

specific can approach. for the thank What’s guess, Fycompa. heard Fycompa be right, earlier on Are the call the is into and rare epilepsies question, in medicine believe All any you. a potential that indications, developing you there precision I mentioned in? Fycompa One I utilized in you if you epilepsy evolving correctly, epilepsy

There actually that. can said, with prescribe press epilepsies be have responds rare may were patient would label clinical physician be Fycompa rare But that not epilepsy presents those other a there’s release whether on broad I a different Fycompa the description epilepsy and determine that to rare fairly seven identified. of drug. ago. to have epilepsies or published too clinical seven did that epilepsies we that If current already for treated characteristics specific a able for been characteristics, the develop, label not as with paper, well already to been of that that identified long contains the rare a With on recently regard in a

do the clinical doing continue the maturity update to anticipate call epilepsies to we trials is relevant product, specifically to MSLs of rare that formal any the this Because Fycompa. relative of but not the of treatment rate information our with label any specific physician will to team provide of out epilepsies, for community

once quarter for questions, Okay, the congratulations on again. taking you thank our and

Pete. Thank you

are McEnany questions to over you. There at closing for no would back further comments. to time. Thank I hand Patrick the this any floor like

thank forward I’d call. us everybody today our to day. we next great to Have a joining like and earnings for look

concludes This today’s conference.

lines your your you participation. this time. at for Thank disconnect may You